Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer
Yiwei Zhong,Xiaoming Lyu,Mingwei Huang,Lei Zheng,Shuming Liu,Yan Shi,Wenjie Wu,Jie Zhang,Jianguo Zhang,Zhong Yiwei,Lyu Xiaoming,Huang Mingwei,Zheng Lei,Liu Shuming,Shi Yan,Wu Wenjie,Zhang Jie,Zhang Jianguo
DOI: https://doi.org/10.1016/j.radonc.2023.110022
IF: 6.901
2023-12-03
Radiotherapy and Oncology
Abstract:Background and purpose Salivary gland cancers (SGCs) are hard to treat when inoperable, and sole brachytherapy appears to be a promising therapeutic strategy. This study aimed to evaluate the effectiveness, safety, and capability of pain palliation using sole brachytherapy for inoperable, recurrent, and irradiated SGCs. Materials and methods Patients with inoperable SGCs treated using sole brachytherapy at XXX were retrospectively included. Patients were divided into primary and recurrent groups and irradiated and non-irradiated groups. Local control (LC), overall survival (OS), radiation-relevant toxicities, and Visual Analogue Scale (VAS) score for pain, were recorded and evaluated. Results A total of 176 patients from 2006 to 2020 were included. The 5-year LC rate was 48.6%; for the primary, recurrent, non-irradiated groups and irradiated groups, the rates were 72.6%, 39.5%, 56.8%, and 34.5%, respectively. The 5-year OS rates was 52.6%; for the primary, recurrent, non-irradiated, and irradiated groups, the rates were 62.9%, 48.6%, 58.9%, and 42.3%, respectively. The mean ± standard deviation of posttreatment VAS score of pain was 2.154 ± 2.989, which was significantly decreased from the score of 6.923 ± 2.280 prior to brachytherapy. Skin hyperpigmentation, mucositis, and dysphagia were the most frequently reported adverse events. Conclusions Brachytherapy as a sole modality, was retrospectively proven effective and safe in the management of inoperable SGCs and was beneficial in multiple irradiation and pain control.
oncology,radiology, nuclear medicine & medical imaging